Search | Clinical Trials Finder

Conditions: Diabetes, Diabetic Foot Ulcer, Edema
Interventions: Conventional Therapy, Venous Stent(s); Device
Lead sponsor: Windsor Ting; Other
Eligibility: 30 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Hyperinsulinemic Hyperglycemic Clamp; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type2 Diabetes, Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Todd Doyle; Other
Eligibility: 40 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 101
States / cities: Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more

Conditions: Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions: anecortave acetate; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Ketogenic Diet, Standard Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions: ETBX-011, ALT-803; Biological
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Diabetes Mellitus, Gestational Diabetes Mellitus (GDM)
Interventions: GDM Enhanced, Meals; Behavioral
Lead sponsor: California Polytechnic State University-San Luis Obispo; Other
Eligibility: 18 Years and older · Female only
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: San Luis Obispo, California • Chicago, Illinois • Providence, Rhode Island

Conditions: Type2 Diabetes
Interventions: PilAm Go4Health Weight-loss Program, Active Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes, Type 1, Diabetes, Type 2
Interventions: Technosphere® Insulin Inhalation Powder, Usual Care; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,053 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 82
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 138
States / cities: Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more

Conditions: Pancreatic Cancer
Interventions: ixabepilone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 95
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Diabetes Mellitus
Interventions: BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD; Drug
Lead sponsor: N-Gene Research Laboratories, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • Paramount, California • Tustin, California + 17 more

Conditions: Ovarian Cancer
Interventions: Sorafenib, Topotecan; Drug
Lead sponsor: Daniela Matei, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Complications
Interventions: Diabetes Tune-Up Group; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes Mellitus
Interventions: Duodenal-jejunal Bypass; Procedure
Lead sponsor: Sound Shore Medical Center of Westchester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New Rochelle, New York

Conditions: Advanced and Selected Solid Tumors
Interventions: BKM120, GSK1120212; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions: Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 11
States / cities: Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Diabetes
Interventions: Apollo Evolution Investigational BG Monitoring System; Device
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Mishawaka, Indiana

Conditions: Type 2 Diabetes
Interventions: Education and patient liaison combination, Control group; Behavioral
Lead sponsor: Meharry Medical College; Other
Eligibility: 21 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Complications
Interventions: CeraVe Hydrating Cleanser, CeraVe Moisturizing Cream; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Cancer
Interventions: MeIQx, Pancreatectomy; Radiation · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection; Drug · Device
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Anne Noonan; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs

PilAm Go4Health Weight Loss Program to Prevent Heart Disease

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Electronic Diabetes Tune-Up Group (eDTU) for African Americans

Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study of an Investigational Glucose Meter System

Type 2 Diabetes Self-management Intervention for Low-income Women

CeraVe Diabetes Mellitus

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer